Zydus closes $166M Assertio buyout for US oncology foothold
What's the deal? Zydus LifesciencesDealroom has a profile for this one. Try Dealroom → has completed its acquisition of US-based Assertio Holdings through a cash tender offer, executed via wholly owned subsidiary Zara Merger Sub Inc. The $166.4 million deal, at $23.50 per share, makes Assertio a wholly owned subsidiary and delists it from Nasdaq.
What's the endgame? The acquisition hands Zydus an immediate US specialty-oncology sales platform, centred on Assertio's Rolvedon — an FDA-approved biologic for chemotherapy-induced neutropenia — plus its oncology commercial relationships. It fits Zydus's broader push into US specialty medicines, including biosimilar launches, as it diversifies beyond generics.
Why now? The deal followed a competitive process. Assertio switched from a $21.80-per-share agreement with Garda TherapeuticsDealroom has a profile for this one. Try Dealroom → to Zydus's $23.50 cash offer, which its board deemed superior.
At the tender offer's expiry on June 15, 2026, shareholders tendered 4,286,488 shares — roughly 66.32% of Assertio's outstanding stock. Zydus accepted all validly tendered shares and completed the merger, converting remaining shares into the same cash consideration.
Also in motion: Zydus is widening its manufacturing base. Through a joint venture with Sunshine Healthcare, Zydus Sunshine Lifesciences has committed more than $20 million to a pharmaceutical facility in Horana, Sri Lanka, with Zydus holding 50% equity. Commercial operations are expected by 2028, aimed at supplying Sri Lanka's retail market and cutting its import dependence.
The signal: For Zydus, the modest price tag belies the strategic value — direct access to US specialty commercialisation rather than scale. The dual moves reflect a generics-heavy manufacturer buying its way up the value chain while expanding its regional production footprint.
Read more: multibagg.ai
Image credit: Generated with Gemini
